Amvuttra
What Amvuttra is used for
Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Amvuttra
- Active substance
- vutrisiran
- Disease area
- Amyloid Neuropathies, Familial
- Medicine group
- Other nervous system drugs
- ATC code
- N07XX18
- Marketing authorisation holder
- Alnylam Netherlands B.V.
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Amvuttra
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Amvuttra used for?
Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
What is the active substance in Amvuttra?
Amvuttra contains vutrisiran.
Who makes Amvuttra?
The EU marketing authorisation holder is Alnylam Netherlands B.V..
Is Amvuttra an orphan medicine?
Yes. Amvuttra is designated an orphan medicine in the EU, for a rare disease (Amyloid Neuropathies, Familial).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU